OverviewChartNewsTraderScreen

PHN/  PLPHN0000014  /

IDC Poland
8/14/2024  12:22:10 PM Chg. 0.00 Volume Bid9:10:00 PM Ask9:10:00 PM High Low
10.00PLN 0.00% 327
Turnover: 3,270		 -Bid Size: - -Ask Size: - 10.00 10.00
GlobeNewswire 6/21 Acasti Announces Year-End 2024 Financial Results, Provides Business Update
GlobeNewswire 5/28 Acasti Pharma to Attend BIO International Convention 2024
GlobeNewswire 1/7 Curevo Vaccine Announces Positive Topline Results from Phase 2 Trial of Amezosvatein, a Next-Generat...
GlobeNewswire 10/3/2023 Rita And Alex Hillman Foundation Doubles Funding For Early-Stage, Nursing-Driven Innovations
GlobeNewswire 9/12/2023 Scilex Holding Company Presented Oral and Poster Presentations on ZTlido (lidocaine topical system) ...
GlobeNewswire 9/12/2023 Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate...
GlobeNewswire 9/7/2023 Sorrento Therapeutics Announces Positive Phase 2a Clinical Trial Results for Resiniferatoxin (RTX) f...
GlobeNewswire 8/15/2023 Velatura HIE Corporation and Premier Health Network Announce Launch of CareConvene in Georgia
Newsfile Corp 1/17/2023 Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3...
Newsfile Corp 9/21/2022 Acasti Pharma Inc. Discusses Clinical Progress of Lead Assets and 2022 Catalysts with The Stock Day ...
Newsfile Corp 7/7/2022 Acasti Pharma Inc. Discusses Year-End Results and Clinical Development Progress with The Stock Day P...
GlobeNewswire 3/22/2022 Acasti Pharma Announces Patents for GTX-104 in Europe, GTX-102 in the U.S. and GTX-101 in Japan
GlobeNewswire 3/20/2022 Sorrento Reports Promising Results With a Universal Chimeric mRNA COVID-19 Vaccine That Elicits Pote...
GlobeNewswire 3/17/2022 Scilex Holding Company, a Majority-Owned Subsidiary of Sorrento Therapeutics, Inc., to Become Public...
GlobeNewswire 3/9/2022 Acasti Pharma CEO to Present at the 32nd Annual Oppenheimer Healthcare Conference on March 16th
GlobeNewswire 3/2/2022 Sorrento Announces COVISHIELD (STI-9199) Antibody Nasal Drops Prevent Productive SARS-CoV-2 Infectio...
GlobeNewswire 3/2/2022 Sorrento Announces FDA Authorization to Proceed With Phase 1 Study Of Intranasal STI-9199 (COVISHIEL...
GlobeNewswire 3/2/2022 NX Development Corp. (NXDC) Names Salvatore DeSena, M.D., as Chief Executive Officer
GlobeNewswire 2/28/2022 Acasti Pharma Celebrates Rare Disease Day
GlobeNewswire 2/28/2022 Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Cli...
Newsfile Corp 2/22/2022 Acasti Pharma Inc. CEO, Jan D'Alvise, Is Featured on The Stock Day Podcast
GlobeNewswire 2/17/2022 Sorrento Announces That It Has Acquired a Majority Ownership in Diagnostic Manufacturer Zhengzhou Fo...
GlobeNewswire 2/14/2022 Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022
GlobeNewswire 2/7/2022 Acasti Pharma Schedules Third Quarter Fiscal 2022 Business Update Conference Call
GlobeNewswire 1/28/2022 Sorrento Announces Its Oral SARS-CoV-2 Main Protease (Mpro) Inhibitor, STI-1558, Strongly Neutralize...